# Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.

> **NCT00171340** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 1065 (actual)

## Conditions studied

- Bone Loss
- Breast Cancer

## Interventions

- **DRUG:** Zoledronic acid
- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT00171340
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-05
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 1065 (ACTUAL)
- **Last updated:** 2012-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00171340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00171340, "Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00171340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*